BiotechTube
Ichnos Glenmark Innovation

Ichnos Glenmark Innovation

New York, United States· Est.
iginnovate.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $120M

Overview

Ichnos Glenmark Innovation (IGI) is a private, clinical-stage biotech advancing a pipeline of novel multispecific antibodies for oncology, powered by its proprietary BEAT® protein engineering platform. Its lead asset, ISB 2001, is a trispecific T-cell engager in Phase 1b for multiple myeloma, with additional preclinical programs targeting immune modulation. The company is led by an experienced management team with deep oncology drug development expertise and operates from innovation centers in the USA, Switzerland, and India.

Oncology

Technology Platform

Proprietary BEAT® technology platform for designing full-length, humanized multispecific antibodies with flexible immune cell engagement and manufacturability. Also developing IMMUNITE™ platform for multimodal immunotherapy.

Funding History

1
Total raised:$120M
Series A$120M

Opportunities

The trispecific design of ISB 2001 offers a potential best-in-class profile for multiple myeloma by targeting two tumor antigens to overcome escape mechanisms.
The flexible BEAT® platform could generate a sustained pipeline of novel multispecifics for large oncology markets, including solid tumors.

Risk Factors

High clinical development risk as lead asset is only in Phase 1b.
Intense competition in multiple myeloma and immuno-oncology from larger, well-funded players.
Platform risk regarding the ability to consistently generate effective and manufacturable multispecific candidates.

Competitive Landscape

IGI competes in the crowded and fast-moving multispecific antibody space for oncology. In multiple myeloma, direct competitors include companies with approved BCMA/CD3 bispecifics (e.g., Johnson & Johnson, Pfizer) and BCMA CAR-T therapies. Its differentiation relies on its trispecific approach and proprietary engineering platforms.

More companies in Biologics / Biosimilars →More companies in United States →